Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

23.54 -0.27 (-1.15%)
Streaming Delayed Price Updated: 9:31 AM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Biggest Jumps In Dividend Yields
While the tariff situation has created a great deal of uncertainty and stock prices have crashed in tow, one silver lining is that dividend yields have at least ticked up. 
Via Talk Markets
Topics Stocks / Equities World Trade
Most active S&P500 stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Down 62%, Should You Buy the Dip on Pfizer?
The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices. 
Via The Motley Fool
Topics Government
Stay informed about the most active stocks in the S&P500 index on Monday's session.
Stay informed about the most active stocks in the S&P500 index on Monday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
Why Health Care Select Sector SPDR Fund (XLV) Is Moving
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major... 
Via Benzinga
Topics Government
4 Dividend Stocks to Double Up on Right Now
Try not to let market volatility bring you down. Instead, let dividend stocks make you happy. These high-yield dividend stocks will pay you between 3% and 7% to hold them. 
Via The Motley Fool
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
What's going on in today's session: S&P500 most active stocks
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for... 
Via Chartmill
3 High Yield Stocks Trading Near 52-Week Lows
With the market pullback, many quality dividend stocks are buying opportunities near their 52-week lows. 
Via Talk Markets
Topics Stocks / Equities
Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts
For many investors, dividend-focused stocks and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day 
Via Benzinga
Topics Retirement
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
Via The Motley Fool
Topics Intellectual Property
Is Pfizer Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
2 Absurdly Cheap Stocks to Buy and Hold for Years
Via The Motley Fool
Topics Intellectual Property
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients
NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda. 
Via Benzinga
Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful
Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall... 
Via Stocktwits
Why Major Pharmaceutical Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government World Trade
3 Value Stocks Worth Buying In Current Market Conditions
Big Pharma, Big Tech and REIT is on the value menu. Discount opportunities at this level are rare. 
Via Talk Markets
Topics Stocks / Equities
Curious about the most active S&P500 stocks in today's session?
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles. 
Via Investor's Business Daily
Topics Workforce
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities. 
Via MarketBeat
3 Ultra-High-Yield Dividend Stocks to Buy in April
Via The Motley Fool
Topics Energy
Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns. 
Via The Motley Fool
The Vanguard S&P 500 ETF Is Sinking, but This Wall Street Analyst Predicts It Will Soar 168% by 2030
Via The Motley Fool
Topics ETFs Economy Stocks
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
From Pfizer Inc.
Via Business Wire
Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification. 
Via Benzinga
Topics ETFs Economy
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events. 
Via Benzinga
Why I Just Bought These 3 Ultra-High-Yield Dividend Stocks
Via The Motley Fool
Topics Energy
What Does the Market Think About Pfizer?
 
Via Benzinga
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025. 
Via Benzinga
Topics Intellectual Property
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback